Hsin‐An Hou

7.6k total citations
162 papers, 3.3k citations indexed

About

Hsin‐An Hou is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Hsin‐An Hou has authored 162 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 116 papers in Hematology, 75 papers in Molecular Biology and 58 papers in Genetics. Recurrent topics in Hsin‐An Hou's work include Acute Myeloid Leukemia Research (95 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (53 papers) and Multiple Myeloma Research and Treatments (19 papers). Hsin‐An Hou is often cited by papers focused on Acute Myeloid Leukemia Research (95 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (53 papers) and Multiple Myeloma Research and Treatments (19 papers). Hsin‐An Hou collaborates with scholars based in Taiwan, United States and Hong Kong. Hsin‐An Hou's co-authors include Hwei‐Fang Tien, Wen‐Chien Chou, Jih‐Luh Tang, Ming Yao, Woei Tsay, Shang‐Yi Huang, Mei‐Hsuan Tseng, Bor‐Sheng Ko, Chien‐Yuan Chen and Shang‐Ju Wu and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Hsin‐An Hou

147 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hsin‐An Hou Taiwan	34	2.2k	1.8k	932	636	417	162	3.3k
Katharina S. Götze Germany	29	2.7k 1.3×	1.7k 1.0×	1.3k 1.4×	510 0.8×	498 1.2×	130	3.9k
Felicitas Thol Germany	33	2.7k 1.3×	2.1k 1.2×	1.1k 1.2×	622 1.0×	464 1.1×	125	4.0k
Valeria Visconte United States	29	1.8k 0.9×	1.4k 0.8×	860 0.9×	426 0.7×	406 1.0×	181	3.2k
Elli Papaemmanuil United States	30	1.6k 0.7×	1.6k 0.9×	650 0.7×	641 1.0×	402 1.0×	99	3.0k
Hideki Makishima United States	32	2.5k 1.2×	2.1k 1.2×	1.4k 1.5×	443 0.7×	357 0.9×	134	4.0k
John Nicoll United States	18	1.9k 0.9×	935 0.5×	1.4k 1.5×	535 0.8×	506 1.2×	30	3.2k
David A. Sallman United States	31	2.6k 1.2×	1.6k 0.9×	1.0k 1.1×	384 0.6×	992 2.4×	293	3.8k
Martin Wermke Germany	25	2.2k 1.0×	1.2k 0.7×	885 0.9×	289 0.5×	1.2k 2.8×	152	3.7k
Brigitte Mohr Germany	30	3.5k 1.6×	1.3k 0.8×	1.3k 1.4×	389 0.6×	558 1.3×	79	4.2k
Wan‐Jen Hong United States	20	1.5k 0.7×	1.3k 0.7×	469 0.5×	318 0.5×	455 1.1×	53	2.2k

Countries citing papers authored by Hsin‐An Hou

Since Specialization

Citations

This map shows the geographic impact of Hsin‐An Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hsin‐An Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hsin‐An Hou more than expected).

Fields of papers citing papers by Hsin‐An Hou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hsin‐An Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hsin‐An Hou. The network helps show where Hsin‐An Hou may publish in the future.

Co-authorship network of co-authors of Hsin‐An Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Hsin‐An Hou. A scholar is included among the top collaborators of Hsin‐An Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hsin‐An Hou. Hsin‐An Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bose, Prithviraj, Hsin‐An Hou, Wojciech Homenda, et al.. (2024). Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis. Blood. 144(Supplement 1). 483–483. 3 indexed citations

Lin, Chien‐Chin, Chi‐Yuan Yao, Chang‐Tsu Yuan, et al.. (2024). IDH2 mutation accelerates TPO‐induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo. SHILAP Revista de lepidopterología. 5(4). 738–748.

Tien, Feng‐Ming, Chi‐Yuan Yao, Cheng‐Hong Tsai, et al.. (2024). Dysregulated immune and metabolic pathways are associated with poor survival in adult acute myeloid leukemia with CEBPA bZIP in-frame mutations. Blood Cancer Journal. 14(1). 8 indexed citations

Tsai, Cheng‐Hong, Feng‐Ming Tien, Mei‐Hsuan Tseng, et al.. (2023). Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification. Blood Cancer Journal. 13(1). 120–120. 12 indexed citations

Yao, Chi‐Yuan, Chien‐Chin Lin, Fabio M. R. Amaral, et al.. (2023). A three‐gene leukaemic stem cell signature score is robustly prognostic in chronic myelomonocytic leukaemia. British Journal of Haematology. 201(2). 302–307. 2 indexed citations

Ward, Grace, Amy F. McLemore, Amy L. Aldrich, et al.. (2023). Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes. International Journal of Molecular Sciences. 24(4). 3896–3896. 23 indexed citations

Tsai, Cheng‐Hong, Feng‐Ming Tien, Yuan‐Yeh Kuo, et al.. (2023). Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer Journal. 13(1). 4–4. 17 indexed citations

Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2023). Clinico‐genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification. American Journal of Hematology. 98(3). 398–407. 6 indexed citations

Lin, Chien‐Chin, Cheng‐Hong Tsai, Feng‐Ming Tien, et al.. (2023). Clinico-Genetic and Prognostic Analyses of 635 Patients with Myelodysplastic Neoplasms Based on the 2022 World Health Organization Classification. Blood. 142(Supplement 1). 1878–1878. 1 indexed citations

10.

Tsai, Cheng‐Hong, Chien‐Chin Lin, Feng‐Ming Tien, et al.. (2023). Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia. American Journal of Hematology. 98(5). 760–769. 19 indexed citations

11.

Lin, Chien‐Chin, Bettina Wingelhofer, Fabio M. R. Amaral, et al.. (2023). Higher MDMX expression was associated with hypomethylating agent resistance and inferior survival in MDS patients, inferring it a potential therapeutic target. Leukemia. 37(12). 2507–2511. 1 indexed citations

12.

Yao, Chi‐Yuan, Yuren Chen, Chang‐Tsu Yuan, et al.. (2022). Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair. Oncogene. 41(11). 1576–1588. 6 indexed citations

13.

Yao, Chi‐Yuan, Chien‐Chin Lin, Chia‐Lang Hsu, et al.. (2022). The clinical and biological characterization of acute myeloid leukemia patients with S100A4 overexpression. Journal of the Formosan Medical Association. 122(7). 636–647. 1 indexed citations

14.

Yao, Chi‐Yuan, Chien‐Chin Lin, Chi‐Ling Chen, et al.. (2022). Higher RUNX1 expression levels are associated with worse overall and leukaemia‐free survival in myelodysplastic syndrome patients. SHILAP Revista de lepidopterología. 3(4). 1209–1219. 4 indexed citations

15.

Hou, Hsin‐An, et al.. (2021). Effectiveness of induction regimens on survival outcome in acute myeloid leukemia patients: a real-world data from 2001 to 2015. Annals of Hematology. 101(1). 109–118. 1 indexed citations

16.

Lin, Chien‐Chin, Chi‐Yuan Yao, Chia‐Lang Hsu, et al.. (2021). Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome. British Journal of Haematology. 196(1). 156–168. 3 indexed citations

17.

Tsai, Cheng‐Hong, Jih‐Luh Tang, Feng‐Ming Tien, et al.. (2021). Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML. Blood Advances. 5(10). 2456–2466. 38 indexed citations

18.

Lin, Chien‐Chin, Chi‐Yuan Yao, Hsin‐An Hou, et al.. (2020). Knock-out of Hopx disrupts stemness and quiescence of hematopoietic stem cells in mice. Oncogene. 39(28). 5112–5123. 16 indexed citations

19.

Yassin, Mohamed A., Alì Taher, Vikram Mathews, et al.. (2018). Myeloproliferative Neoplasms in Asia, Including Middle East, Turkey, and Algeria: Epidemiological Indices and Treatment Practice Patterns from the Multinational, Multicenter, Observational MERGE Registry. Blood. 132(Supplement 1). 5461–5461. 2 indexed citations

20.

Wei, Tong‐You Wade, Pei‐Yu Wu, Ting‐Jung Wu, et al.. (2016). Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA. Cancer Research. 77(2). 494–508. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact